Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 180

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 180
---
If product liability lawsuits are successfully brought against DiamiR, DiamiR may incur substantial liabilities and may have to limit or cease sales of its products.

The testing, manufacturing, and marketing of medical diagnostic products
involves an inherent risk of product liability claims. If DiamiR cannot successfully defend itself against product liability claims, DiamiR
may incur substantial liabilities or be required to limit or cease sales of its products. In addition, a defect in the design or manufacture
of DiamiR’s products could have a material adverse effect on DiamiR’s reputation in the industry and subject DiamiR to claims
of liability for injury and otherwise. Any substantial loss resulting from such a claim could have a material adverse effect on DiamiR’s
profitability and the damage to DiamiR’s reputation in the industry could have a material adverse effect on DiamiR’s business.

<div align='center'>95

TRADEMARKS, SERVICE MARKS AND TRADENAMES</div>

This prospectus contains trademarks,
service marks and trade names of others, which are the property of their respective owners. Solely for convenience, the trademarks, service
marks, logos and trade names referred to in this prospectus are included without the ® and ™ symbols. All trademarks, service
marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our
use or display of other companies’ trademarks, service marks, copyrights, or trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies or unrelated parties.

<div align='center'>USE OF PROCEEDS</div>

We will not receive any proceeds from the sale of any of the Class
A Ordinary Shares by the Selling Securityholders. We have agreed to pay all expenses relating to registering the Class A Ordinary Shares
covered by this prospectus. The Selling Securityholders will pay any brokerage commissions and/or similar charges incurred in connection
with the sale of the Class A Ordinary Shares covered hereby.

We will receive proceeds if
any of the 2025 Warrants are exercised at the exercise prices per share (assuming the exercise price of $2.00 per share for the October
2025 Warrants and $2.50 for the Placement Agent Warrants) for cash which, if exercised in full, would result in gross proceeds of approximately
$4.15 million. The exercise of the 2025 Warrants, and any proceeds we may receive